ASH COVID-19 Resources for Hematologists

ASH President’s Message:

As the world grapples with the novel coronavirus, ASH believes that we can help each other be as knowledgeable and prepared as possible. The information and links below will get us started but please let us know how ASH can help you, your center and your patients. The website will be updated frequently and new features added as needed.

— ASH President Stephanie J. Lee, MD, MPH

Read more from Dr. Lee on things for researchers to consider if their labs need to shut down.

Share this post

Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."